Navigation Links
Cantel Medical's Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
Date:10/13/2009

LITTLE FALLS, N.J., Oct. 13 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex International subsidiary, has launched a unique face mask treated with BIOSAFE(®) antimicrobial in markets outside the United States. Crosstex' new BIOSAFE-treated Ultra Sensitive face masks begin to reduce microorganisms, such as MRSA, VRE and Staph, immediately upon contact. These treated face masks have proven to be effective against Influenza A strains, such as seasonal flu and the novel H1N1 virus.

Gary Steinberg, CEO of Crosstex, stated, "Face masks serve as the first line of defense against airborne particles by trapping them in the filter media. However, live microorganisms can continue to live on the mask surface. Our new BIOSAFE-treated Ultra Sensitive face masks enhance the functionality of the mask by effectively killing the harmful microorganisms, reducing the cross-contamination risk from touching the mask itself and creating a safer environment upon disposal of the mask. The BIOSAFE treatment additive, as approved by the EPA, is compatible with our manufacturing process. We are impressed that the BIOSAFE treatment chemically binds to the outer mask surface, creating a long-lasting shield against microbial contamination. Even better, because BIOSAFE mechanically kills cells, it will not cause the development of more resistant 'superbugs'."

Cantel's President and CEO, Andrew Krakauer, explained, "BIOSAFE is an important component of our strategic plan to expand our liquid chemical germicide business and invest more aggressively in research and development. Given the unique performance, manufacturability and cost advantages of this additive, Cantel has embarked on a number of internal R&D initiatives to incorporate BIOSAFE into additional infection prevention and contr
'/>"/>

SOURCE Cantel Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
2. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
5. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
6. New Places and People - Truphatek opens USA subsidiary
7. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
8. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
9. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
(Date:8/20/2014)... The National Association of Drug Diversion ... by the real-time, pseudoephedrine (PSE) blocking system in ... Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales and ... and make arrests. Data released by NPLEx shows ... blocked the sale of more than 7,481 boxes of ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ... receiving concomitant systemic antibiotics in two Phase 3 clinical ... the treatment of adult patients with Clostridium difficile ... 1 issue of Clinical Infectious Diseases (CID). ...
... Aug. 16, 2011 Marshall Edwards, Inc. (Nasdaq: ... clinical development of novel therapeutics targeting cancer metabolism, announced ... ME-143 (formerly NV-143), the Company,s lead NADH oxidase inhibitor, ... Administration (FDA). The Company plans to initiate a Phase ...
Cached Medicine Technology:Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 2Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 3Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 4Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 5Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin 6Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 2Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143 3
(Date:8/22/2014)... 22, 2014 Dealing with a drug or ... the addict is a child. Adolescent substance abuse has been ... long time. But a new helpline is now providing a ... youth rehab for something like a teen drug addiction ... to help make a positive impact in the community. By ...
(Date:8/22/2014)... According to the market research report "Blind ... (ACC) System Market for Passenger Cars; by Geography ... by MarketsandMarkets, classifies and defines the automotive BSD ... and value. The report highlights potential growth opportunities ... review of the market drivers, restrains, growth indicators, ...
(Date:8/21/2014)... Petersburg, FL (PRWEB) August 22, 2014 The ... behind those fine lines, wrinkles and sagging of skin. ... loss. , "By age 40, the body has lost about ... has lost about 45%," says Kathy Heshelow, founder of Sublime ... with less of it - well, we know what happens." ...
(Date:8/21/2014)... York, NY (PRWEB) August 21, 2014 ... can often have larger discounts for specific protection plans, ... is now helping consumers to quote life insurance from ... , The local agents that appear inside of ... offer a fast method of price reviews this year. ...
(Date:8/21/2014)... 21, 2014 AVEC Health Solutions, ... the addition of Kerry Gillespie as Chief Executive ... management experience, Gillespie brings an extremely robust background ... management positions with prominent industry leading organizations across ... President of Triad Isotopes, Inc. a private nuclear ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... was issued,today by the law firm of Schiffrin Barroway Topaz ... class action lawsuit was filed in the,United States District Court ... of securities of Healthways Inc. (Nasdaq: HWAY ),("Healthways" or ... (the "Class Period")., If you wish to discuss this ...
... The University of Illinois at Chicago is one of ... Norway to participate in the Clinical Islet Transplant Consortium ... researchers have begun clinical studies to test new approaches ... and fewer side effects for adults with difficult-to-control type ...
... U.S. Senate to vote soon on legislation that ... New Hampshire, WASHINGTON, July 8 Seniors ... to the Medicare Advantage,program in legislation being considered ... cut $6.6 million from the Medicare Advantage program ...
... Pittsburgh-led researchers could provide new insight into how ... arteriovenous malformations (AVMs)develop in humans, as reported in ... . , Led by Beth Roman, an assistant ... Arts and Sciences, the team created the first ...
... rates no different than ,watchful waiting, study shows , , ... therapy used for localized prostate cancer may not bestow ... with a simple "wait-and-see" approach. , Men taking androgen ... promote tumor growth, even had a slightly lower ...
... From the Committee to Reduce Infection Deaths (RID), ... to be,proud of," says Betsy McCaughey, Chairman of the ... of New York State. The New York,State Hospital-Acquired Infection ... performance with national infection,rate averages, and finds the state ...
Cached Medicine News:Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:New Hampshire Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 3Health News:It's the Same Old Song: 'Accentuate the Positive' as New York State Department of Health Releases Statewide Hospital Infection Rates 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: